Insulin glulisine

Insulin glulisine

Clinical data
ATC code	A10AB06 (WHO)
Identifiers
CAS Number	207748-29-6
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C258H384N64O78S6
Molar mass	5823

WikiDoc Resources for Insulin glulisine
Articles
Most recent articles on Insulin glulisine Most cited articles on Insulin glulisine Review articles on Insulin glulisine Articles on Insulin glulisine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Insulin glulisine Images of Insulin glulisine Photos of Insulin glulisine Podcasts & MP3s on Insulin glulisine Videos on Insulin glulisine
Evidence Based Medicine
Cochrane Collaboration on Insulin glulisine Bandolier on Insulin glulisine TRIP on Insulin glulisine
Clinical Trials
Ongoing Trials on Insulin glulisine at Clinical Trials.gov Trial results on Insulin glulisine Clinical Trials on Insulin glulisine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Insulin glulisine NICE Guidance on Insulin glulisine NHS PRODIGY Guidance FDA on Insulin glulisine CDC on Insulin glulisine
Books
Books on Insulin glulisine
News
Insulin glulisine in the news Be alerted to news on Insulin glulisine News trends on Insulin glulisine
Commentary
Blogs on Insulin glulisine
Definitions
Definitions of Insulin glulisine
Patient Resources / Community
Patient resources on Insulin glulisine Discussion groups on Insulin glulisine Patient Handouts on Insulin glulisine Directions to Hospitals Treating Insulin glulisine Risk calculators and risk factors for Insulin glulisine
Healthcare Provider Resources
Symptoms of Insulin glulisine Causes & Risk Factors for Insulin glulisine Diagnostic studies for Insulin glulisine Treatment of Insulin glulisine
Continuing Medical Education (CME)
CME Programs on Insulin glulisine
International
Insulin glulisine en Espanol Insulin glulisine en Francais
Business
Insulin glulisine in the Marketplace Patents on Insulin glulisine
Experimental / Informatics
List of terms related to Insulin glulisine

Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, it is 3B-lysine-29B-glutamic acid-human insulin, has the empirical formula C₂₅₈H₃₈₄N₆₄O₇₈S₆ and a molecular weight of 5823. It was developed by Sanofi-Aventis and sold under the trade name Apidra®. When injected subcutaneously, it appears in the blood earlier and at higher concentrations that human insulin. When used as a meal time insulin, the dose should be given within 15 minutes before a meal or within 20 minutes after starting a meal.

External links

• Apidra® Homepage
• http://www.genome.jp/dbget-bin/www_bget?dr:D04540